Balance Sheet

Cash Flow Statement

Acquisitions Asset Writedowns and Impairment Asset Writedowns and Impairment Beginning Cash Balance Beginning Cash Balance Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Sunshine Biopharma (SBFM) Share-based Compensation (2016 - 2024)

Sunshine Biopharma filings provide 9 years of Share-based Compensation readings, the most recent being $12000.0 for Q1 2024.

On a quarterly basis, Share-based Compensation changed N/A to $12000.0 in Q1 2024 year-over-year; TTM through Dec 2024 was $12000.0, a N/A change, with the full-year FY2024 number at $12000.0, changed N/A from a year prior.
Share-based Compensation hit $12000.0 in Q1 2024 for Sunshine Biopharma, down from $918000.0 in the prior quarter.
In the past five years, Share-based Compensation ranged from a high of $918000.0 in Q1 2021 to a low of $12000.0 in Q1 2024.
Median Share-based Compensation over the past 3 years was $50000.0 (2020), compared with a mean of $326666.7.